When Standard Immunotherapy Doesn't Work, Try This Instead

In this episode, Dr. Dino Prato navigates the complexities of treating cancers that appear invisible to the immune system, making traditional immunotherapy for cancer less effective.

He explains how building custom immunotherapies and changing tumor information can overcome these limitations, offering new avenues for cancer treatment. This discussion is crucial for anyone interested in advancements in oncology and how precision oncology is shaping the future of care, focusing on immune responses.

🎯 What You’ll Learn in This Episode:
- What “cold tumors” really mean
- Why KRAS drugs slow cancer but rarely finish it
- What microsatellite stability actually tells doctors
- Why PD-1 inhibitors fail most patients long-term
- How precision oncology turns cold tumors hot
- The role of spatial biology and immune mapping
- Why direct-to-tumor therapy releases immune targets
- The right questions to ask when told “nothing else can be done”

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Cancer isn’t beaten by managing it — it’s beaten when the immune system can finally see it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493